Status:
COMPLETED
A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will determine the maximum tolerated dose and the dose-limiting toxicities of RO4987655 in patients with advanced and/or metastatic solid tumors. In the first part of the study, groups of p...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- advanced and/or metastatic cancer not amenable to standard therapy;
- any solid tumor type (Part 1); malignant melanoma or other responsive tumor type (Part 2);
- measurable and/or evaluable disease (Part 1); \>=1 measurable lesion (Part 2);
- ECOG performance status 0-2.
Exclusion
- prior chemotherapy, radiotherapy or immunotherapy within 28 days of first receipt of study drug;
- prior corticosteroids as anti-cancer therapy within 14 days of first receipt of study drug;
- active CNS lesions;
- acute or chronic infection.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
145 Patients enrolled
Trial Details
Trial ID
NCT00817518
Start Date
January 1 2009
End Date
December 1 2014
Last Update
September 2 2015
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Marseille, France, 13385
2
Paris, France, 75231
3
Paris, France, 75651
4
Villejuif, France, 94805